SCHEDULE 13G: Ayrton Capital and Affiliates Disclose 5.71% Stake in ReShape Lifesciences Inc.
Beneficial Ownership Disclosure
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly disclosed beneficial ownership of 5.71% of ReShape Lifesciences Inc.'s common stock, primarily through warrants.
Summary
- Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in ReShape Lifesciences Inc.
- Each Reporting Person beneficially owns 200,000 shares of ReShape Lifesciences Inc. common stock.
- This ownership represents 5.71% of the Issuer's common stock, calculated based on 3,305,087 shares outstanding as of February 18, 2025, plus the 200,000 shares issuable upon warrant exercise.
- The 200,000 shares are issuable upon the exercise of certain warrants held by the Reporting Persons.
- The issuable shares are subject to a 9.99% beneficial ownership blocker.
- Alto Opportunity Master Fund, SPC Segregated Master Portfolio B is a private investment vehicle managed by Ayrton Capital LLC, with Waqas Khatri serving as the managing member of Ayrton Capital LLC and a director of the Fund.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.
Industry Context
This filing is a standard disclosure of a significant ownership stake by an investment entity and its principals in a publicly traded company. It reflects an investment decision by the reporting persons in ReShape Lifesciences Inc., a company operating in the medical devices or healthcare sector, specifically related to weight loss solutions.
Stakeholder Impact
- Shareholders: The disclosure of a significant beneficial ownership stake by an investment fund and its principals provides transparency regarding the company's ownership structure. This can influence investor perception and potentially signal confidence or strategic interest from the reporting entities.
Key Dates
| Date | Description |
|---|---|
| 2025-02-18 | Date as of which 3,305,087 shares of Common Stock of the Issuer were outstanding, as stated in the Issuer's Proxy Statement on Schedule 14A. |
| 2025-03-14 | Date of the Issuer's Proxy Statement on Schedule 14A filing. |
| 2025-03-31 | Date of event which requires the filing of this statement, and the holdings of the Reporting Persons reported herein. |
| 2025-05-14 | Date of filing of this Schedule 13G statement. |
Keywords
ReShape Lifesciences Inc., beneficial ownership, Schedule 13G, common stock, warrants, Ayrton Capital LLC, Alto Opportunity Master Fund, Waqas Khatri, SEC filing, investment management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.